TAVR Asymptomatic Approval: A New Era for Early...

By João L. Carapinha

May 6, 2025

The U.S. Food and Drug Administration (FDA) has approved the Edwards Lifesciences Sapien 3 family of balloon-expandable transcatheter aortic valve replacement (TAVR) devices for treating asymptomatic severe aortic stenosis (AS). This marks a signi...

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.